Denali Therapeutics Inc.
DNLI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | 0.34 | -1.22 | 0.04 |
| FCF Yield | -10.85% | -12.58% | -7.52% | -4.06% |
| EV / EBITDA | -7.79 | -15.96 | -10.09 | -18.06 |
| Quality | ||||
| ROIC | -37.61% | -18.16% | -30.88% | -28.62% |
| Gross Margin | 0.00% | 94.94% | 93.52% | 88.47% |
| Cash Conversion Ratio | 0.82 | 2.47 | 0.75 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 89.38% | -31.38% | 22.18% |
| Free Cash Flow Growth | 1.97% | -41.28% | -19.40% | -153.23% |
| Safety | ||||
| Net Debt / EBITDA | 0.29 | 0.42 | 0.48 | 0.82 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -1.41 | 0.00 |
| Cash Conversion Cycle | -521.49 | -203.16 | -373.11 | -301.79 |